Study of the novel non-xanthine heterocyclic compound GU285 as a potent non-selective adenosine receptor antagonist in the rat

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 3, 2002, Pages 175-181

  Harden, Fiona A ^a   Brown, Lindsay ^a   Quinn, Ronald J ^a   Harrison, Glenn J ^a   Headrick, John P ^a   Rose'Meyer, Roselyn B ^a   Willis, Roger J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Adenosine, antagonist, receptor; CAS 134896 40 5; GU285, adenosine receptor binding study, rat; Pyrazolo 3,4 d pyrimidine derivative

Indexed keywords

4 AMINO 6A CARBAMOYLETHYLTHIO 1 PHENYLPYRAZOLO[3,4 D]PYRIMIDINE; ADENOSINE RECEPTOR BLOCKING AGENT; GU 285; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONOTROPISM; COMPETITIVE INHIBITION; CORONARY BLOOD VESSEL; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; GEOMETRY; HEART RATE; INOTROPISM; MALE; NONHUMAN; RAT; RECEPTOR BINDING;

EID: 0036195412     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299876     Document Type: Article

References (21)

1. Pyrazolo[3,4-d]pyrimidines, a new class of adenosine antagonists
2. Pyrazolo[3,4-d]pyrimidines as adenosine antagonists
3. Synthesis and adenosine receptor affinity of a series of pyrazolo[3,4-d]pyrimidine analogues of 1-methylsoguanosine
4. Mono-α-carbamoylethylthio-substituted pyrazolo[3,4-d]pyrimidines: The position of substitution
5. 6-phenylisopropyladenosine
6. 2 receptors in rat brain
7. Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations
8. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1.3-dipropylxanthine to rat brain membranes
9. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) - A selective high affinity antagonist radioligand for A1 adenosine receptors
10. A simplification of the protein assay of Lowry et al. which is generally more applicable
11. A method to evaluate the response of the coronary circulation of perfused rat heart to adenosine
12. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated?
13. Adenosine reduces catecholamine contractile responses in oxygenated and hypoxic atria
14. Endogenous adenosine inhibits catecholamine contractile responses in normoxic hearts
15. Endogenous adenosine improves work rate to oxygen consumption ratio in catecholamine stimulated isovolumic rat heart
16. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors
17. A biphasic response to adenosine in the coronary vasculature of the K+ arrested perfused rat heart
18. Agerelated changes to adenosine in rat coronary resistance vessels
19. The non-xanthine heterocyclic compound SCH58261 is a new potent and selective adenosine A2A receptor antagonist
20. Conformational induction versus conformational selection: Evidence from allosteric enhancers
21. Purine receptors in mammalian tissues: Pharmacology and functional significance